Gyre Therapeutics Statistics
Total Valuation
GYRE has a market cap or net worth of $661.11 million. The enterprise value is $609.63 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GYRE has 91.31 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | 91.31M |
| Shares Outstanding | 91.31M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | -12.33% |
| Owned by Insiders (%) | 6.97% |
| Owned by Institutions (%) | 3.68% |
| Float | 20.95M |
Valuation Ratios
The trailing PE ratio is 131.51.
| PE Ratio | 131.51 |
| Forward PE | n/a |
| PS Ratio | 5.67 |
| Forward PS | 4.74 |
| PB Ratio | 6.24 |
| P/TBV Ratio | 6.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 654.57 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 121.27 |
| EV / Sales | 5.23 |
| EV / EBITDA | 43.51 |
| EV / EBIT | 53.05 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.60, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.60 |
| Quick Ratio | 4.58 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 8.21% and return on invested capital (ROIC) is 9.29%.
| Return on Equity (ROE) | 8.21% |
| Return on Assets (ROA) | 4.93% |
| Return on Invested Capital (ROIC) | 9.29% |
| Return on Capital Employed (ROCE) | 7.77% |
| Weighted Average Cost of Capital (WACC) | 39.36% |
| Revenue Per Employee | $186,541 |
| Profits Per Employee | $8,043 |
| Employee Count | 625 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 0.66 |
Taxes
In the past 12 months, GYRE has paid $4.56 million in taxes.
| Income Tax | 4.56M |
| Effective Tax Rate | 31.56% |
Stock Price Statistics
| Beta (5Y) | 6.39 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 7.72 |
| 200-Day Moving Average | 7.67 |
| Relative Strength Index (RSI) | 47.97 |
| Average Volume (20 Days) | 122,766 |
Short Selling Information
The latest short interest is 1.38 million, so 1.51% of the outstanding shares have been sold short.
| Short Interest | 1.38M |
| Short Previous Month | 1.34M |
| Short % of Shares Out | 1.51% |
| Short % of Float | 6.57% |
| Short Ratio (days to cover) | 11.34 |
Income Statement
In the last 12 months, GYRE had revenue of $116.59 million and earned $5.03 million in profits. Earnings per share was $0.02.
| Revenue | 116.59M |
| Gross Profit | 111.17M |
| Operating Income | 11.49M |
| Pretax Income | 14.44M |
| Net Income | 5.03M |
| EBITDA | 14.01M |
| EBIT | 11.49M |
| Earnings Per Share (EPS) | $0.02 |
Full Income StatementBalance Sheet
The company has $52.43 million in cash and $939,000 in debt, with a net cash position of $51.49 million or $0.56 per share.
| Cash & Cash Equivalents | 52.43M |
| Total Debt | 939,000 |
| Net Cash | 51.49M |
| Net Cash Per Share | $0.56 |
| Equity (Book Value) | 142.28M |
| Book Value Per Share | 1.16 |
| Working Capital | 84.08M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.01 million and capital expenditures -$1.19 million, giving a free cash flow of -$180,000.
| Operating Cash Flow | 1.01M |
| Capital Expenditures | -1.19M |
| Depreciation & Amortization | 2.52M |
| Net Borrowing | n/a |
| Free Cash Flow | -180,000 |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
Gross margin is 95.35%, with operating and profit margins of 9.86% and 4.31%.
| Gross Margin | 95.35% |
| Operating Margin | 9.86% |
| Pretax Margin | 12.38% |
| Profit Margin | 4.31% |
| EBITDA Margin | 12.02% |
| EBIT Margin | 9.86% |
| FCF Margin | n/a |
Dividends & Yields
GYRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | 0.76% |
| FCF Yield | -0.03% |
Analyst Forecast
The average price target for GYRE is $17.00, which is 134.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.00 |
| Price Target Difference | 134.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 22.72% |
| EPS Growth Forecast (5Y) | 110.91% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GYRE has an Altman Z-Score of 20.68 and a Piotroski F-Score of 4.
| Altman Z-Score | 20.68 |
| Piotroski F-Score | 4 |
